within Pharmacolibrary.Drugs.ATC.L;

model L04AC04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.12 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 160 / 1000000,
    adminCount     = 1,
    Vd             = 0.0066,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Rilonacept is a dimeric fusion protein acting as an interleukin-1 (IL-1) inhibitor, used primarily in the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle–Wells syndrome (MWS). It is approved for use in the United States for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with cryopyrin-associated periodic syndromes who received rilonacept subcutaneously.</p><h4>References</h4><ol><li><p>Radin, A, et al., &amp; Belomestnov, P (2010). Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD). <i>Journal of clinical pharmacology</i> 50(7) 835–841. DOI:<a href=&quot;https://doi.org/10.1177/0091270009351882&quot;>10.1177/0091270009351882</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20035038/&quot;>https://pubmed.ncbi.nlm.nih.gov/20035038</a></p></li><li><p>Garg, M, et al., &amp; Sanchez, GAM (2017). Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. <i>JCI insight</i> 2(16) –. DOI:<a href=&quot;https://doi.org/10.1172/jci.insight.94838&quot;>10.1172/jci.insight.94838</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28814674/&quot;>https://pubmed.ncbi.nlm.nih.gov/28814674</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC04;
